EUCTR2017-004125-32-PL进行中（未招募）1 期
A randomised, double blind, placebo controlled trial to evaluate the safety, efficacy and pharmakokinetics of Pleconaril as an add on to AchEI/memantine for treatment of patients with Alzheimer’s disease
Apodemus Aktiebolag0 个研究点目标入组 120 人开始时间: 2018年4月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male or female patients diagnosed with AD according to ICD-10
- •2) Age 60 to 85 years (inclusive) at the time of informed consent
- •3) Patient has stable AChEI and/or memantine for dementia (stable treatment is defined as stable in type of treatment and dose for at least 3 months prior to the baseline visit)
- •4) MMSE score 20 to 27 (inclusive) and judged by the Investigator to be able to give informed consent
- •5) Patients have adequate hearing, vision, and language skills to perform neuropsychiatric testing and interviews as specified in the protocol, as judged by the Investigator
- •6) 12-lead ECG with normal tracings; or changes that are not clinically significant and do not require medical intervention, as judged by the Investigator
- •7) Patient has a relative or caregiver, judged as reliable by the Investigator, who has signed informed consent.
- •The relative or caregiver should participate in the patient’s visits at the clinic and assist the patient with drug compliance at home.
- •8) Willingness to participate after signing informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 95
排除标准
- •1) Active hepatitis B, active hepatitis C, or HIV infection
- •2) Serious cardiac disease including unstable or uncontrolled cardiac disease during the last 6 months and/or previous history of deep vein thrombosis or clinical signs of deep venous thrombosis
- •3) Major psychiatric disorder (e.g. schizophrenia or past or present major depression disorder or as judged by the investigator)
- •4) Major surgical procedure within 4 weeks prior to inclusion
- •5) Women of childbearing potential (WOCBP) without reliable contraceptive method.
- •For the purpose of this trial, WOCBP includes any female who had experienced menarche, who had not undergone tubal ligation, and who is not postmenopausal. Post menopause was defined as amenorrhea = 12 consecutive months without another cause.
- •6) Previous stroke
- •7) Unstable treatment with Vitamin B12 medication, thyroid disorder medication, TNF-alpha blocking agents, antidepressants, cholinergic drugs, other AD medications (e.g. souvenaid)
- •Unstable treatment is defined as unstable in type of treatment and dose in the 3 months prior to the baseline visit. (Therefore, all patients not requiring such treatment or with stable treatment may be included)
- •8) Participation in any other clinical trial within 30 days of inclusion (randomisation) in the trial or patients with unresolved investigational treatment-related adverse events
- •9) Other chronic disease or previous organ transplantation judged by the Investigator to interfere with the assessment of treatment success and/or ability to fully participate in the trial
- •10) Patients that require immunosuppressive treatments including azathioprine, ciclosporin, systemic steroid treatment (e.g. prednisolone at doses of =10 mg/day or hydrocortisone) or has received such treatment within the last 6 months prior to randomization
- •11) Patients that are treated with drugs that can interact significantly with Pleconaril; ethinylestradiol
- •12) Lack of suitability for participation in the trial, for any reason, as judged by the Investigator
研究者
相似试验
进行中（未招募）
1 期
A randomised, double blind, placebo controlled trial to evaluate the safety, efficacy and pharmakokinetics of Pleconaril as an add on to AchEI/memantine for treatment of patients with Alzheimer’s diseaseAlzheimer's diseaseEUCTR2017-004125-32-CZApodemus Aktiebolag120
已完成
3 期
Investigating the feasibility and acceptability of synbiotic supplementation in patients with chronic kidney disease (pre-dialysis)Renal and Urogenital - Kidney diseaseDiet and Nutrition - Other diet and nutrition disordersChronic Kidney DiseaseACTRN12617000324314A/Prof Katrina Campbell68
已完成
3 期
A topical cold sore treatment containing St John's Wort, Calendula and CopperHerpes Simplex LabialisSkin - Dermatological conditionsAlternative and Complementary Medicine - Herbal remediesInfection - Other infectious diseasesACTRN12618000890235Western Sydney University272
已完成
4 期
Antibiotics for bronchiectasis exacerbations in children - The Bronchiectasis Exacerbation Study (Study 1).BronchiectasisRespiratory - Other respiratory disorders / diseasesACTRN12612000011886Qld Children's Medical Research Institute189
进行中（未招募）
不适用
A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAMymphangioleiomyomatosisMedDRA version: 9.1Level: LLTClassification code 10049459Term: LymphangioleiomyomatosisMedDRA version: 9.1Level: PTClassification code 10049459Term: LymphangioleiomyomatosisEUCTR2007-003745-32-GBniversity of Nottingham